| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Integrative Physiology |
From the Departments of Pathology and Laboratory Medicine (M.K.F., N.S.) and Medical Microbiology and Immunology (M.K.F., A.A.), University of Minnesota-Duluth, School of Medicine, Duluth, Minn; and the NeuroBiotechnology Center (J.P.-T., P.K.), Ohio State University, Columbus, Ohio.
Correspondence to M. Kent Froberg, Department of Pathology, UMD-School of Medicine, 10 University Dr, Duluth, MN 55812. E-mail kfroberg{at}d.umn.edu
Cardiovascular disease is the leading cause of mortality in the United States. Atherosclerosis is responsible for most of this pathology and is an inflammatory disease with multiple cytokines and adhesion molecules expressed during atherogenesis. Cytomegalovirus (CMV), monocytes, and monocyte chemoattractant protein-1 (MCP-1) have all been implicated in human atherogenesis. A transgenic mouse overexpressing MCP-1 in the myocardium and pulmonary arteries develops myocarditis and pulmonary vascular inflammation. We infected MCP-1 transgenic mice with a sublethal dose of murine cytomegalovirus (MCMV) to look for evidence of accelerated inflammation in vascular tissues overexpressing MCP-1 to determine if MCMV could interact with monocytes and MCP-1 in a manner similar to what may occur in atherogenesis. MCMV infection of MCP-1 transgenic mice caused ascites, myocarditis, and pulmonary artery inflammation, which was not present in mock-infected MCP-1 or MCMV-infected wild-type mice. Inflammatory infiltrates in these tissues consisted of macrophages and T lymphocytes similar to the infiltrates seen in atherosclerosis. Virus presence in inflamed tissues was demonstrated by infecting transgenic mice with MCMV recombinant virus containing the gene sequence for the enhanced green fluorescent protein (EGFP). Human CMV could be involved in atherogenesis in a similar manner by interacting with monocytes and MCP-1 specifically expressed in vascular walls.
Key Words: cytomegalovirus atherosclerosis monocyte chemoattractant protein-1 monocytes
This article has been cited by other articles:
![]() |
C. N. Paiva, R. T. Figueiredo, K. Kroll-Palhares, A. A. Silva, J. C. Silverio, D. Gibaldi, A. d. S. Pyrrho, C. F. Benjamim, J. Lannes-Vieira, and M. T. Bozza CCL2/MCP-1 controls parasite burden, cell infiltration, and mononuclear activation during acute Trypanosoma cruzi infection J. Leukoc. Biol., November 1, 2009; 86(5): 1239 - 1246. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. W. Distler, A. Akhmetshina, G. Schett, and O. Distler Monocyte chemoattractant proteins in the pathogenesis of systemic sclerosis Rheumatology, February 1, 2009; 48(2): 98 - 103. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Stern and B. Slobedman Human Cytomegalovirus Latent Infection of Myeloid Cells Directs Monocyte Migration by Up-Regulating Monocyte Chemotactic Protein-1 J. Immunol., May 15, 2008; 180(10): 6577 - 6585. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Krebs, E. Scandella, B. Bolinger, D. Engeler, S. Miller, and B. Ludewig Chronic Immune Reactivity Against Persisting Microbial Antigen in the Vasculature Exacerbates Atherosclerotic Lesion Formation Arterioscler Thromb Vasc Biol, October 1, 2007; 27(10): 2206 - 2213. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Cid, M. P. Hoffman, J. Hernandez-Rodriguez, M. Segarra, M. Elkin, M. Sanchez, C. Vilardell, A. Garcia-Martinez, M. Pla-Campo, J. M. Grau, et al. Association between increased CCL2 (MCP-1) expression in lesions and persistence of disease activity in giant-cell arteritis Rheumatology, November 1, 2006; 45(11): 1356 - 1363. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K. Froberg, D. Dannen, A. Adams, J. Parker-Thornburg, and P. Kolattukudy Murine Cytomegalovirus Infection Markedly Reduces Serum MCP-1 Levels in MCP-1 Transgenic Mice. Ann. Clin. Lab. Sci., March 1, 2006; 36(2): 179 - 184. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. H. Shen, L. Zhang, B. Utama, J. Wang, Y. Gan, X. Wang, J. Wang, L. Chen, G. M. Vercellotti, J. S. Coselli, et al. Human cytomegalovirus inhibits Akt-mediated eNOS activation through upregulating PTEN (phosphatase and tensin homolog deleted on chromosome 10) Cardiovasc Res, February 1, 2006; 69(2): 502 - 511. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Petrakopoulou, M. Kubrich, S. Pehlivanli, B. Meiser, B. Reichart, W. von Scheidt, and M. Weis Cytomegalovirus Infection in Heart Transplant Recipients Is Associated With Impaired Endothelial Function Circulation, September 14, 2004; 110(11_suppl_1): II-207 - II-212. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Ludewig, P. Krebs, and E. Scandella Immunopathogenesis of atherosclerosis J. Leukoc. Biol., August 1, 2004; 76(2): 300 - 306. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.H. Shen, B. Utama, J. Wang, M. Raveendran, D. Senthil, W.J. Waldman, J.D. Belcher, G. Vercellotti, D. Martin, B.M. Mitchelle, et al. Human Cytomegalovirus Causes Endothelial Injury Through the Ataxia Telangiectasia Mutant and p53 DNA Damage Signaling Pathways Circ. Res., May 28, 2004; 94(10): 1310 - 1317. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K. Froberg CMV Escapes! Ann. Clin. Lab. Sci., April 1, 2004; 34(2): 123 - 130. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Weis, T. N. Kledal, K. Y. Lin, S. N. Panchal, S. Z. Gao, H. A. Valantine, E. S. Mocarski, and J. P. Cooke Cytomegalovirus Infection Impairs the Nitric Oxide Synthase Pathway: Role of Asymmetric Dimethylarginine in Transplant Arteriosclerosis Circulation, February 3, 2004; 109(4): 500 - 505. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. N. Streblow, C. Kreklywich, Q. Yin, V. T. De La Melena, C. L. Corless, P. A. Smith, C. Brakebill, J. W. Cook, C. Vink, C. A. Bruggeman, et al. Cytomegalovirus-Mediated Upregulation of Chemokine Expression Correlates with the Acceleration of Chronic Rejection in Rat Heart Transplants J. Virol., February 1, 2003; 77(3): 2182 - 2194. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |